CI

At a glance

ClinicalIndex Comparison Record
Phase 4Recruiting· 100 target
Drug / intervention
Dexmedetomidine-esketamine combination +1 moredrug
Likely dose
Dexmedetomidine-esketamine combination 1 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06566482
NCT06566482Phase 4RecruitingUpdate OverdueUpdated 21mo ago · Completion was 9mo ago
Enrollment Stalled
Update Overdue

Mini-dose Dexmedetomidine-Esketamine Supplemented Analgesia for Postoperative Sleep Promotion in Patients at High-risk of Obstructive Sleep Apnea: A Randomized Trial

Peking University First Hospital·interventional·Posted Aug 22, 2024·Updated Sep 25, 2024

In Brief

A Phase 4 clinical trial evaluating Dexmedetomidine-esketamine combination and Placebo for Obstructive Sleep Apnea and 4 related conditions. Currently recruiting, targeting 100 participants across 1 site.

Signals

Enrollment appears stalled

Detailed Summary

Patients with obstructive sleep apnea (OSA) are at increased risk of developing sleep disturbances after surgery. Dexmedetomidine is a highly selective α2-adrenergic agonist with sedative, analgesic, and anxiolytic effects. Ketamine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist. Esketamine is the S-enantiomer of racemic ketamine and twice as potent as racemic ketamine for analgesia. A recent trial showed that mini-dose esketamine-dexmedetomidine in combination with opioids improved analgesia and subjective sleep quality after scoliosis correction surgery. This trial is designed to test the hypothesis that mini-dose dexmedetomidine-esketamine supplemented analgesia may improve postoperative sleep quality in patients at high-risk of OSA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4RecruitingOverdue
20252026
First PostedAug 22, 2024
Enrollment StartSep 11, 2024
Primary CompletionSep 1, 2025
Study CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 12 monthsPosted 1.9 years ago

Interventions

Dexmedetomidine-esketamine combinationdrug

Patient-controlled analgesia is established with dexmedetomidine (1 μg/ml), esketamine (1 mg/ml), and sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.

Placebodrug

Patient-controlled analgesia is established with sufentanil (1 μg/ml) in a total volume of 100 ml. The pump is programmed to deliver 2-ml boluses at 6 to 8-minute lockout intervals with a background infusion rate at 1 ml/h. Patient-controlled analgesia is provided for at least 24 hours but no more than 48 hours after surgery.